FDA Drug Shortage Database
Sodium bicarbonate shortage
The FDA Drug Shortage Database lists 4 of 15 sodium bicarbonate presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on March 1, 2017. 7 more presentations are on the list as available.
- Generic listed
- In shortage
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 5ml injection | 2 | 0 | 0 |
| 42mg/1ml injection | 0 | 2 | 1 |
| 50ml injection | 1 | 1 | 0 |
| 75mg/1ml injection | 0 | 0 | 1 |
| 84mg/1ml injection | 1 | 4 | 2 |
Which presentations are listed?
Limited or unavailable now (4)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01) | Hospira, Inc., a Pfizer Company | Current posted March 1, 2017, updated September 22, 2026 | Limited Availability; Other |
| Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02) | Hospira, Inc., a Pfizer Company | Current posted March 1, 2017, updated September 22, 2026 | Limited Availability; Other |
| Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35) | Hospira, Inc., a Pfizer Company | Current posted March 1, 2017, updated September 22, 2026 | Unavailable; Other |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1) | Amphastar Pharmaceuticals, Inc. | Current posted March 1, 2017, updated October 5, 2026 | Limited Availability; Demand increase for the drug |
Listed now, available (7)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4) | Exela Pharma Sciences, LLC | Current posted July 24, 2017, updated October 1, 2026 | Available |
| Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05) | Fresenius Kabi USA, LLC | Current posted July 24, 2017, updated October 6, 2026 | Available |
| Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14) | Hospira, Inc., a Pfizer Company | Current posted March 1, 2017, updated September 22, 2026 | Available |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5) | Exela Pharma Sciences, LLC | Current posted July 24, 2017, updated October 1, 2026 | Available |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4) | Exela Pharma Sciences, LLC | Current posted July 24, 2017, updated October 1, 2026 | Available |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50) | Fresenius Kabi USA, LLC | Current posted July 24, 2017, updated October 6, 2026 | Available |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3) | Long Grove Pharmaceuticals LLC | Current posted March 1, 2017, updated October 1, 2026 | Available |
Resolved or discontinued (4)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14) | Hospira, Inc., a Pfizer Company | To Be Discontinued posted November 7, 2025, updated November 7, 2025 | not given |
| Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14) | Hospira, Inc., a Pfizer Company | To Be Discontinued posted November 7, 2025, updated November 7, 2025 | not given |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14) | Hospira, Inc., a Pfizer Company | To Be Discontinued posted November 7, 2025, updated November 7, 2025 | not given |
| Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14) | Hospira, Inc., a Pfizer Company | To Be Discontinued posted November 7, 2025, updated November 7, 2025 | not given |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Calcium carbonate and famotidine and magnesium hydroxide | Acid reflux and ulcers | No current entry | 20 labelers | $0.258 per tablet Acid reducer complete tablet chewable |
| Calcium carbonate | Acid reflux and ulcers | No current entry | none listed | $0.0315 per tablet 750 mg tablet chewable |
| Omeprazole | Acid reflux and ulcers | A presentation being discontinued | 118 labelers | $0.0295 per capsule 20 mg capsule |
| Famotidine | Acid reflux and ulcers | No current entry | 145 labelers | $0.0289 per tablet 20 mg tablet |
| Esomeprazole | Acid reflux and ulcers | No current entry | 116 labelers | $0.145 per capsule 20 mg capsule |
| Pantoprazole | Acid reflux and ulcers | No current entry | 66 labelers | $0.0358 per tablet 40 mg tablet |
| Lansoprazole | Acid reflux and ulcers | No current entry | 59 labelers | $0.106 per capsule 30 mg capsule |
| Sucralfate | Acid reflux and ulcers | No current entry | 43 labelers | $0.173 per tablet 1 g tablet |
| Metoclopramide | Acid reflux and ulcers | No current entry | 39 labelers | $0.0439 per tablet 10 mg tablet |
| Cimetidine | Acid reflux and ulcers | No current entry | 18 labelers | $0.236 per tablet 300 mg tablet |
| Rabeprazole | Acid reflux and ulcers | No current entry | 20 labelers | $0.224 per tablet 20 mg tablet |
| Magnesium oxide | Acid reflux and ulcers | No current entry | none listed | $0.0346 per tablet 400 mg tablet |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage